Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st 3 Qtrs Business Results
February 21, 2005
- 2/3 of Ethical Drugs Designated as "Rx-only Drugs"
February 21, 2005
- Korosho to Demand PIII Data in NDA for Anticancer Agents
February 21, 2005
- Handling of Applications for Add'l Indications of Anticancer Drugs Notified
February 21, 2005
- Add. Indications Approved for 45 Drugs Used Off-label: JAPIC Seminar
February 21, 2005
- REGULATORY NEWS IN BRIEF
February 21, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 21, 2005
- MONITOR
February 21, 2005
- Aiming at Acquiring "Absolute No.1" in Diagnostic Market: Mr Ogawa of RDKK
February 21, 2005
- The Society of Japanese Pharmacopoeia Seminar
February 21, 2005
- OTC NEWS IN BRIEF
February 21, 2005
- Kringle, Galeni Make Research Evaluation Accord
February 21, 2005
- FPMAJ's GL on Handling of Personal Information Announced
February 21, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 21, 2005
- JPEC to Start GMP Compliance Certification for Pharm. Excipients
February 21, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 21, 2005
- Alfresa to Train MSs to Help Boost Profits, Cut Costs
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3Qtrs Business Results
February 14, 2005
- Drug Administration Is at Crossroads: New GAD Director
February 14, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…